Company / Cash & Equivalents
Candel Therapeutics, Inc. Cash & Equivalents History
FY2021-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$35.4M
FY2023
5-year range
$35.4M / $82.6M
FY2021-FY2023
Trend
-49.5%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $83M to $35M over the past 2 years.
Based on SEC 10-K filings.
$35M in FY2023.
Declined from $83M to $35M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2023, cash & equivalents decreased 49.5% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -5.13 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2023 | $35.4M | -49.5% |
| FY2022 | $70.1M | -15.2% |
| FY2021 | $82.6M | - |
As of FY2023 · SEC 10-K · Updated Jun 24, 2026